Inotiv (NOTV) Expected to Announce Earnings on Wednesday

Inotiv (NASDAQ:NOTV) is anticipated to release its earnings data after the market closes on Wednesday, February 5th. Analysts expect Inotiv to post earnings of ($0.32) per share and revenue of $121.83 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Inotiv (NASDAQ:NOTV) last released its quarterly earnings data on Tuesday, December 3rd. The company reported ($0.16) earnings per share (EPS) for the quarter. Inotiv had a negative return on equity of 15.86% and a negative net margin of 22.10%. On average, analysts expect Inotiv to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Inotiv Price Performance

Shares of NASDAQ:NOTV opened at $4.28 on Monday. The company’s fifty day moving average price is $4.37 and its 200 day moving average price is $2.75. Inotiv has a 12 month low of $1.23 and a 12 month high of $11.42. The company has a debt-to-equity ratio of 2.29, a current ratio of 1.37 and a quick ratio of 1.22. The firm has a market capitalization of $111.32 million, a P/E ratio of -1.02 and a beta of 3.59.

Insider Buying and Selling

In other news, Director David Landman bought 23,529 shares of the stock in a transaction dated Thursday, December 19th. The shares were acquired at an average price of $4.25 per share, with a total value of $99,998.25. Following the completion of the acquisition, the director now directly owns 176,851 shares in the company, valued at approximately $751,616.75. The trade was a 15.35 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Michael J. Harrington bought 10,000 shares of the stock in a transaction dated Friday, December 6th. The stock was purchased at an average cost of $3.98 per share, for a total transaction of $39,800.00. Following the acquisition, the director now owns 37,500 shares of the company’s stock, valued at approximately $149,250. This represents a 36.36 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 71,029 shares of company stock worth $314,248 in the last ninety days. 7.80% of the stock is owned by corporate insiders.

About Inotiv

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.